DrugDashboards

Furosemide

furosemide · FUROSEMIDE 10 mg/mL · Injection, Solution · Intravenous · Baxter Healthcare Corporation

NDC 36000-0282-25 · 25 VIAL, SINGLE-DOSE in 1 BOX / 2 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

21 companies supply this market — deep enough that no single failure threatens the supply. The generic price is up 13% over the past year, to $0.4616 per mL. The brand (Furosemide) runs $0.4616 per mL — 1.7× more. It is in shortage right now — FDA lists the reason as “other”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.4616per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.0180per billing unit (1 MG)HCPCS J1938 · Jul 1, 2026
  • Part D plans paid (avg)$896.08per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 23155-0473-44) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$0.3480per unit
middle half $0.2430–$0.3912 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.3480
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$0.25$0.5$0.75Apr 2024Sep 2026$0.4616
19 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$0.68
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.018
HCPCS J1938 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$10,901
2,894 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

35● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • in shortage now+25
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for furosemide (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · price up 19% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $6.22 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA202747
TE code
AP
Approval date
Jan 27, 2014
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)Apr 7, 2020
    Other
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)Apr 7, 2020
    Other
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • Planned discontinuation — Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)Apr 7, 2020
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)Apr 7, 2020
    Discontinuation of the manufacture of the drug
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • Planned discontinuation — Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)Apr 7, 2020
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)Apr 7, 2020
    Other
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)Apr 7, 2020
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)Apr 7, 2020
    Other
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)Apr 7, 2020
    Demand increase for the drug
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of furosemide (Injection, Solution)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CorporationFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Camber Pharmaceuticals, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Cardinal Health 107, LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Devatis Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Gland Pharma LimitedFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Henry Schein, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Lifestar Pharma LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
NorthStar Rx LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Sagent PharmaceuticalsFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Avenacy Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Civica, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCFUROSEMIDE 40 mg/4mLJul 15, 2026Sep 2, 2026
Eugia US LLCFUROSEMIDE 100 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.FUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Phlow CorporationFUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Remedyrepack Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstFUROSEMIDE 10 mg/mLJul 15, 2026Aug 31, 2026
ProPharma DistributionFUROSEMIDE 10 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Furosemide — NDC 36000-0282-25," retrieved September 3, 2026, https://drugdashboards.com/drug/36000028225.

Free to cite with attribution — see how the data is put together.